As the migration of circulating monocytes into the arterial intima and their subsequent differentiation into fat-laden foam cells are critical events in the development of atherosclerosis, the molecular mechanisms underpinning these two events have been the focus of much study in recent years. In particular, since the seminal studies of Goldstein et al. 1 revealed almost 30 years ago that foam cell formation could be triggered by the uptake of oxidized low-density lipoprotein (oxLDL) by macrophage scavenger receptors in vitro, much interest has been focused on the potential of scavenger receptors to modulate atherosclerosis.
To date, the class B scavenger receptor CD36 has received the most attention in this context since early studies identified it as a key mediator of oxLDL uptake in vitro.
2 However, the results that have emerged from subsequent studies of CD36 function in vivo are both complex and conflicting. 3 Febbraio et al. 4, 5 were the first to report the results of breeding mice genetically deficient in both CD36 and apolipoprotein E (ApoE), showing that CD36 deficiency reduced aortic lesion formation by 76% and that bone-marrow-specific deletion of CD36 also reduced atherosclerosis in ApoE -/-mice. However, the pro-atherogenic potential of CD36 was soon challenged by Freeman and colleagues, 6 who reported that genetic deletion of CD36, or the related scavenger receptor SR-A, had no effect on atherosclerosis in their systems and suggested that insufficient backcrossing or differences in ambient microbial exposure may have influenced the results reported by Febbraio et al. Febbraio and colleagues 7 responded by showing that even at late time points, CD36 deficiency continued to afford protection to ApoE -/-mice in their experimental systems and that concurrent deletion of SR-A did not extend this protection further. 8 Nevertheless, a follow-up study by Freeman et al. reported that concurrent deletion of both SR-A and CD36 in ApoE -/-mice had little impact on aortic lesion area in their experimental systems. 9 Interestingly, although a consensus has yet to emerge regarding the role of CD36 in murine atherogenesis, both groups agree that there appears to be no deficiency in foam cell formation in ApoE -/-mice deficient in CD36, SR-A, or both. [4] [5] [6] [7] [8] [9] This remarkable observation contrasts with expectations derived from in vitro experimentation 1, 2 and suggests that foam cell formation may occur via pathways that are independent of scavenger receptors or oxLDL uptake in vivo. Moreover, these studies pose the key question of how else might CD36 deficiency modulates atherosclerosis in some experimental settings?
Harb et al. 10 report that the expression of CD36 by macrophages may play a regulatory role in their migration to atherosclerotic lesions. Specifically, the authors showed that the recruitment of radiolabelled macrophages to atherosclerotic lesions was reduced by pre-treatment of ApoE -/-mice with the CD36-binding peptide EP80317 and that the reduction in recruitment of macrophages was not altered if the macrophages were from CD36-deficient mice. The authors thus conclude that CD36 expression by macrophages appears to play a key role in their recruitment to the artery wall.
Notably, this is not the first implication of a role for CD36 in the regulation of macrophage migration. Kuchibhotla et al. 8 showed recently that CD36-deficient macrophages display reduced chemotaxis towards the chemokine CCL2. Paradoxically, however, Park et al.
11 also reported that macrophage migration could be inhibited by oxLDL in a CD36-dependent manner. Thus, whereas the studies of Harb et al. and Kuchibhotla et al. suggest that CD36 expression somehow promotes macrophage migration, the results of Park et al. suggest that engagement of CD36 by oxLDL inhibits macrophage migration. One potential explanation for these apparently conflicting results may lie in recent evidence that ligand binding to CD36 can regulate specific intracellular signalling pathways related to cellular migration and inflammation. 8, 10, 11 Park et al. found that treatment of macrophages with oxLDL induced actin polymerization and cell spreading in a CD36-dependent manner via activation of focal adhesion kinase (FAK) and inactivation of Src homology 2-containing phosphotyrosine phosphatase, thereby inhibiting cellular migration. 11 In
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contrast, Harb et al. 10 show that EP80317 reduced the phosphorylation of the FAK Pyk2 induced by the oxidised phospholipid (and CD36 ligand) POVPC. It is also notable that EP80317 markedly reduced both vascular and circulating inflammatory markers in CD36-sufficient but not CD36-deficient mice, suggesting that engagement of CD36 by EP80317 may in fact promote anti-inflammatory signalling pathways. 10 Earlier studies also showed that EP80317 induced genes involved in cellular cholesterol efflux, such as peroxisome proliferator-activated receptor-g, liver x receptor-a, and the ATP-binding cassette transporters ABCA1 and ABCG1, in CD36-sufficient but not CD36-deficient cells. 12 Given the multitude of pathways identified in these studies that may be regulated by CD36 ligation, a key question that remains to be answered in forthcoming studies is whether the different ligands of CD36 may promote different intracellular signalling pathway. Alternatively, is it possible that some ligands, such as EP80317, may serve as antagonists to physiological CD36 ligands, such as oxLDL? Answering both of these questions will likely be required before a fuller understanding of the thus far conflicting literature is achieved. Even so, it seems likely that the interpretation of such studies will remain challenging, as the ligands recognized by CD36 are remarkably diverse, including such disparate moieties as thrombospondin, collagen, oxLDL, apoptotic cells, long-chain fatty acids, and certain anionic oxidized phospholipids, all of which may play distinct roles in atherogenesis. 3 Moreover, the multiple roles played by CD36 in processes as diverse as lipid transport, clearance of apoptotic cells, intestinal fat absorption, angiogenesis, and cellular adhesion are also likely to prove difficult to dissect in the context of atherosclerosis. 3 The complex roles played by CD36 in regulating such processes are perhaps best exemplified by recent studies of human subjects deficient in CD36 expression. Approximately 3% of the Japanese population bear a genetic deficiency in CD36 that is associated with an increased prevalence of metabolic abnormalities, including hypertension, hyperlipidaemia, and elevated fasting glucose levels. 13 Moreover, plasma triglycerides, apolipoprotein B-48, free fatty acids, and free glycerol levels of CD36-deficient patients were recently shown to be much higher after oral fat loading than those of controls.
14 Although definitive association studies remain to be performed to determine whether human CD36 deficiency correlates with altered cardiovascular risk in such populations, it has been informally noted that CD36 deficiency is three-fold more common in cardiovascular disease patients than controls.
14 Overall, in the light of such diverse findings in different experimental settings, it seems likely that the roles played by CD36 in human and murine atherosclerosis are likely to remain enigmatic until further studies in a number of areas are completed. In the meantime, what we can draw from the current results with some certainty is that the roles played by CD36 in atherosclerosis extend far beyond those of just a scavenger receptor.
